Loading
Latest filing published 31 Oct 2023 for Eagle Pharmaceuticals, INC., €44k.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Michael Graves is a declared insider of Eagle Pharmaceuticals, Inc., with filings sourced from SEC (Form 4). We count 2 filings; the first trade dates from 15 March 2016 and the latest from 27 October 2023.
No open-market sale appears; the market trades are 1 purchase worth €51k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 option exercise.
The latest filing, published on 31 October 2023, reports an option exercise of €44k in Eagle Pharmaceuticals, Inc. The most recent open-market purchase was published on 16 March 2016, 3,873 days ago. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations